Stocktoria

DarioHealth Corp. DRIO

Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
3/9
Piotroski F — financial health
-12.4
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials (annual, from 10-K)

FYRevenueNet incomeGross profitFree cash flowEquity
2025$22.4M-$41.7M$12.7M-$26.1M$67.9M
2024$27.0M-$42.7M$13.3M-$38.7M$72.0M
2023$20.4M-$59.4M$6.0M-$31.0M$58.1M
2022$27.7M-$62.2M$9.7M-$48.3M$80.0M
2021$20.5M-$76.8M$4.0M-$50.7M$85.5M
2020$7.6M-$29.4M$2.5M-$17.9M$28.2M

Recent insider activity (Form 4)

InsiderRoleDateActionSharesPrice
Nelson Steven CharlesPresident and CCO2025-09-11Grant30,000
STERN ADAM Kdirector2025-09-11Grant20,000
Leisure Lawrence B.director2025-09-11Grant20,000
Shaked Yoavdirector2025-09-11Grant20,000
Raphael ErezChief Executive Officer2025-09-11Grant60,000
Franco-Yehuda ChenChief Financial Officer2025-09-11Grant5,000
MCGRATH DENNIS Mdirector2025-09-11Grant20,000
Karah Hiladirector2025-09-11Grant20,000

Why these scores methodology →

Piotroski F-score: 3/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -12.4 (distress)

  • Working capital / assets 0.234
  • Retained earnings / assets -4.107
  • EBIT / assets -0.333
  • Equity / liabilities 1.611

Source: SEC EDGAR filings · CIK 0001533998 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.